MedTrace Logo

The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis

NCT00332397 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1007

Last updated 2008-06-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of 3 different drug-eluting-stent platforms to reduce coronary artery reblockage after stent implantation

Conditions

  • Coronary Disease

Interventions

DEVICE

Rapamycin-eluting Stent

due to randomization, Cypher stent will be implanted

DEVICE

Zotarolimus-eluting Stent

due to randomization, Endeavor stent will be implanted

DEVICE

Rapamycin-eluting Stent

due to randomization, rapamycin-eluting stent will be implanted

Sponsors & Collaborators

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Albert Schoemig, MD · Deutsches Herzzentrum Muenchen

  • Adnan Kastrati, MD · Deutsches Herzzentrum Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332397 on ClinicalTrials.gov